Onesource Specialty Pharma Limited — Board/Management Information 2025

Feb 27, 2025

==> picture [170 x 19] intentionally omitted <==

==> picture [107 x 95] intentionally omitted <==

==> picture [158 x 70] intentionally omitted <==

==> picture [479 x 353] intentionally omitted <==

==> picture [170 x 19] intentionally omitted <==

==> picture [294 x 45] intentionally omitted <==

==> picture [476 x 181] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

A47635

==> picture [170 x 19] intentionally omitted <==

==> picture [480 x 533] intentionally omitted <==

==> picture [385 x 160] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

Dr. Claudio Albrecht

Claudio Albrecht, co-founder and managing partner of Albrecht, Prock & Partners was until August 31st, 2018 CEO of the publicly listed STADA AG. Before this assignment Claudio worked in and with the Generic industry for more than 30 years.

Claudio started his pharmaceutical career at Sandoz in 1987 in Austria and became General Manager of its generic businesses in the Netherlands, in Germany and the USA, before leaving to become CEO of the Ratiopharm Group in 2000. In his time as CEO of the Ratiopharm Group he was driving the internationalization process of the German drug maker beyond Europe and was material for the initiation of the development, manufacturing and commercialization project of Ratiopharm’s Biosimilars program. Ratiopharm was first to market with the Biosimilar Filgrastim in Europe.

In 2007 Claudio founded together with Peter Prock the strategy consulting firm CoMeth in Slovakia before he was asked to assume the role of CEO and Chairman of the Board of the Actavis Group. Actavis was operating in over 50 countries worldwide with standalone 2012 revenues in excess of € 2billion.

Under his leadership, Actavis was sold to Watson for 6 bio US$, which represented an above average industry multiple. As CEO of Actavis Claudio initiated a total turn around process and started a joint venture for the development and commercialization of recombinant Insulin and its Analogues with the objective to build the first Generic “one stop shop” in Diabetes. After the divestiture of Actavis, Claudio founded with Peter Prock the Zug/Switzerland based Albrecht, Prock & Partners AG. Together with Private Equity and strategic investors AP&P worked on numerous acquisition projects amongst which the take private initiative for STADA AG was the most significant. STADA AG was the largest leveraged buyout of a German listed company ever.

Claudio holds a PhD in law.

DEBARATI SEN: Brief Bio:

Ms. Debarati Sen is a highly accomplished global business leader with experience driving transformative business performance through operating and financial expertise. She is currently the Group President for HMTX Industries, a global luxury vinyl tile flooring manufacturer. Ms. Sen has accelerated growth across diversified industrial and consumer businesses, spearheaded turnarounds, strategic M&A and partnerships, and built deep and diverse teams internationally. Most recently Ms. Sen led the largest division in 3M’s Consumer Business Group with household brands such as Filtrete™ filters, Command™ hanging solutions and ScotchBlue™ tapes, a profitable portfolio of brands totaling $2.8 billion in annual sales. Previously as the president of 3M’s heritage business of Industrial Abrasives, she led the strategy for robotics and automation redefining prior boundaries in the metal fabrication industry and has been in demand as a speaker in diversified industrials and industrial automation forums. As the CEO and Managing Director, she also led 3M India Ltd. (NSE/BSE - 3MINDIA), 3M Co’s public entity in India from June of 2016 to June of 2019.

As Treasurer and Trustee of the Women’s Foundation of Minnesota, Ms. Sen leads the Financial Leadership Committee of that organization. She is also currently serving on the Senior Advisory Board of the Global Women’s Network, Carlson School of Management, University of Minnesota She has a bachelor’s degree in Electronics from Maulana Azad National Institute of Technology in Bhopal, India and an MBA in Marketing and Finance from XLRI Jamshedpur in India. She has also been inducted into the Fortune India, Most Powerful Women list in 2018 and won the Business Standard Star MNC of the Year award in 2017.

Vijay Karwal: Bio

Vijay Karwal is a Managing Director of CBC Group, based in Singapore, with over 25 years of global management and advisory experience in the healthcare industry, including an extensive background in strategy, business development, M&A and capital raising gained in roles in industry and as a senior investment banker. Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, with an AUM of US$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate investments, across the healthcare space, including in pharmaceuticals, biotech, medical technology, and healthcare services. In his role at CBC, Vijay advises on sourcing and execution of investment opportunities as well as portfolio management with particular focus on CBC’s credit strategy RBF funds, and regional Southeast Asia coverage for the firm.

He also serves as an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, stock exchange listed and headquartered in Bangkok, Thailand, and as a Non Executive Director of AffaMed Therapeutics Ltd. and AffaMed Technologies, the joint venture between AffaMed Therapeutics and SIFI SpA, a leading international ophthalmology company headquartered in Italy, to develop, manufacture and commercialize premium Intra Ocular Lenses in the Greater China market.

Vijay was previously an Operating Partner of CBC in which capacity he served as Executive Director and CEO of AffaMed Therapeutics, a Shanghai headquartered CBC portfolio company developing innovative solutions for ophthalmic disorders which he first joined as CFO. He joined CBC from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the NYSE-listed global provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, Head of Healthcare Banking in North America at ABN AMRO and RBS, and as a senior member of ABN AMRO Rothschild - the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector representing over $95 billion in transaction value, gaining extensive global experience across postings in London, Chicago, New York, Hong Kong and Singapore.

A native of the Netherlands, Vijay was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charter holder.

==> picture [170 x 19] intentionally omitted <==

==> picture [470 x 178] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [447 x 172] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [452 x 166] intentionally omitted <==

==> picture [170 x 19] intentionally omitted <==

==> picture [58 x 39] intentionally omitted <==

==> picture [76 x 31] intentionally omitted <==

==> picture [479 x 173] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [170 x 19] intentionally omitted <==

==> picture [480 x 262] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 17] intentionally omitted <==

==> picture [265 x 18] intentionally omitted <==

==> picture [265 x 11] intentionally omitted <==

==> picture [100 x 12] intentionally omitted <==

==> picture [407 x 173] intentionally omitted <==

==> picture [39 x 11] intentionally omitted <==

==> picture [35 x 11] intentionally omitted <==

Date: February 27, 2025

The Board of Directors OneSource Specialty Pharma Limited

Dear Sir/ Madam,

Re: Resignation from the Directorship of OneSource Specialty Pharma Limited

I hereby tender my resignation as a Non-Executive Director of OneSource Specialty Pharma Limited due to other professional commitments, with effect from the close of business hours on February 27, 2025.

I take this opportunity to thank the Board of Directors and the Management of the Company for their support during my association with the Company.

Warm regards Mahadevan Narayanamoni